Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Delayed Swiss Exchange  -  08:46:17 2023-01-27 am EST
0.0294 CHF   -0.68%
01/17RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
CI
01/17Relief Therapeutics Wins Review Board's Nod for Planned Clinical Study of Skin Cancer Drug
MT
01/17Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation of RLF-100

11/07/2022 | 01:25am EST

Relief Therapeutics Holding AG announced promising six-month stability data on a new formulation of RLF-100® (aviptadil). The reported data demonstrated high purity levels at six months at all temperatures tested, including at refrigerated and room temperature environments. The results are consistent with those observed at the three-month time period.

Based on these results, Relief has filed a new provisional patent application.


ę S&P Capital IQ 2022
All news about RELIEF THERAPEUTICS HOLDING AG
01/17RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial E..
CI
01/17Relief Therapeutics Wins Review Board's Nod for Planned Clinical Study of Skin Cancer D..
MT
01/17Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating R..
EQ
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVAfor Pati..
AQ
2022Acer Therapeutics' Olpruva Approved by FDA, Triggers Availability of $42.5 Million Loan
MT
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ ..
AQ
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ f..
CI
2022Relief Therapeutics, Acer Therapeutics Win US FDA Nod For Urea Cycle Disorders Treatmen..
MT
2022Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 wit..
EQ
2022Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ ..
EQ
More news
Financials
Sales 2022 12,0 M 13,0 M 13,0 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 130 M 141 M 141 M
Capi. / Sales 2022 10,9x
Capi. / Sales 2023 5,66x
Nbr of Employees 10
Free-Float 71,7%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,03 CHF
Average target price 0,32 CHF
Spread / Average Target 995%
Managers and Directors
Jack M. Weinstein Chief Executive Officer
Jeremy Meinen Chief Financial Officer
Raghuram Selvaraju Chairman
Nermeen Varawalla Chief Medical Officer
Paolo Galfetti Chief Operating Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
RELIEF THERAPEUTICS HOLDING AG-1.33%141
MODERNA, INC.7.49%74 239
LONZA GROUP AG17.19%42 748
IQVIA HOLDINGS INC.11.53%42 445
ALNYLAM PHARMACEUTICALS, INC.-3.63%28 492
SEAGEN INC.8.70%25 936